Alzheimer's Drug Targeting Soluble Amyloid Falls Short in a Large Clinical Trial
A paper reports that solanezumab, a monoclonal antibody-based treatment for Alzheimer’s disease developed by Eli Lilly that targets amyloid plaques, did not significantly slow cognitive decline.
Columbia University Irving Medical Center (CUIMC) led the multicenter study.
Researchers have proposed that Alzheimer’s disease is caused by the buildup of a sticky protein called beta-amyloid. According to this ‘amyloid hypothesis,’ the protein forms plaques in the brain that damage and eventually destroy brain cells. Solanezumab was designed to reduce the level of soluble amyloid molecules before they aggregate.
Click here to read more.
Microsurgical Approaches to Aneurysms and Skull Base Diseases 2018
Nov. 15-17, 2018; Jacksonville, Fla.
2018 Mayo Clinic Multidisciplinary Spine Care Conference
Nov. 16-17, 2018; Amelia Island, Fla.
Craniofacial Surgery and Transfacial Approaches to the Skull Base
Nov. 30-Dec. 2, 2018; St. Louis
Comprehensive Endoscopic Endonasal Surgery of the Skull Base Course
Dec. 5-8, 2018; Pittsburgh
Cervical Spine Research Society - 23rd Instructional Course & 46th Annual Meeting
Dec. 5-8, 2018; Scottsdale, Ariz.